The net worth of Nanobac Pharmaceuticals Incorporated is the difference between its total assets and liabilities. Nanobac Pharmaceuticals' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Nanobac Pharmaceuticals' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Nanobac Pharmaceuticals' net worth can be used as a measure of its financial health and stability which can help investors to decide if Nanobac Pharmaceuticals is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Nanobac Pharmaceuticals Incorporated stock.
Nanobac Pharmaceuticals Net Worth Analysis
Nanobac Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Nanobac Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Nanobac Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Nanobac Pharmaceuticals' net worth analysis. One common approach is to calculate Nanobac Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Nanobac Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Nanobac Pharmaceuticals' net worth. This approach calculates the present value of Nanobac Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Nanobac Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Nanobac Pharmaceuticals' net worth. This involves comparing Nanobac Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Nanobac Pharmaceuticals' net worth relative to its peers.
Enterprise Value
18.98 Million
To determine if Nanobac Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nanobac Pharmaceuticals' net worth research are outlined below:
Nanobac Pharmaceuticals generated a negative expected return over the last 90 days
Nanobac Pharmaceuticals has some characteristics of a very speculative penny stock
Nanobac Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 17.62 K. Net Loss for the year was (6.58 M) with profit before overhead, payroll, taxes, and interest of 3.1 K.
Nanobac Pharmaceuticals Incorporated currently holds about 3.93 K in cash with (910.89 K) of positive cash flow from operations.
Nanobac Pharmaceuticals has a very weakfinancial position based on the latest SEC disclosures
When accessing Nanobac Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Nanobac Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Nanobac Pharmaceuticals' profitability and make more informed investment decisions.
Nanobac Pharmaceuticals has return on total asset (ROA) of (0.3684) % which means that it has lost $0.3684 on every $100 spent on assets. This is way below average. Nanobac Pharmaceuticals' management efficiency ratios could be used to measure how well Nanobac Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Nanobac Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 02/25/2025, Return On Equity is likely to grow to 2.63, though Return On Tangible Assets are likely to grow to (92.96). As of 02/25/2025, Change To Liabilities is likely to grow to about 632.9 K, while Total Current Liabilities is likely to drop slightly above 4.6 M.
Nanobac Pharmaceuticals' management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Enterprise Value Revenue
7.0798
Revenue
17.6 K
Quarterly Revenue Growth
0.866
Nanobac Pharmaceuticals Earnings per Share Projection vs Actual
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.